5 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 3, 2 Early Phase 1, 2 Not applicable, 2 Phase 1, 2 Phase 2.
Follow relmapirazin: new trials by email Literature Review of relmapirazin trials Research Report on relmapirazin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluorescent Probe for Assessment of Renal Elimination Relmapirazin, Iohexol, Medibeacon tGFR monitor - Augmented Renal Clearance, Critical Illness | Phase 4 | Recruiting | Aaron Cook | 200 | 2026-09-01 | 2026-10-07 |
| Evaluation of Protein Loading on Measurement of Renal Reserve Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) - Glomerular Filtration Rate | Not applicable | Not yet recruiting | MediBeacon | 25 | 2026-09-01 | 2026-08-14 |
| MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol - Glomerular Filtration Rate, Heart Failure | Not applicable | Recruiting | MediBeacon | 15 | 2026-08-10 | 2026-08-14 |
| Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries Lumitrace, KARL STORZ POWER LED BLUE System - Ureter Injury | Phase 1 | Active not recruiting | MediBeacon | 10 | 2026-01-30 | 2026-08-13 |
| Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system - Retinopathy, Retinal Vein Occlusion | Early Phase 1 | Recruiting | MediBeacon | 10 | 2025-11-06 | 2026-02-04 |
| Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) - Kidney Diseases, Kidney Injury | Phase 3 | Completed | MediBeacon | 149 | 2023-03-20 | 2025-03-28 |
| A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants MB-102 DMID, MB-102 OMID, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) - Kidney Diseases, Kidney Injury | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 121 | 2023-03-02 | 2024-01-02 |
| Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) - Chronic Kidney Disease | Phase 3 | Completed | MediBeacon | 249 | 2022-06-14 | 2024-04-18 |
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Terminated | Mustang Bio | 3 | 2020-02-17 | 2024-07-22 |
| Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability Lactulose/Rhamnose solution, MB-102 - Crohn Disease | Early Phase 1 | Completed | MediBeacon | 22 | 2019-10-27 | 2022-06-10 |
| Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart - Acute Kidney Injury | Phase 2 | Completed | MediBeacon | 234 | 2016-05-11 | 2023-10-26 |
Kidney Diseases (2) · Renal Insufficiency (2) · Acute Kidney Injury (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Critical Illness (1) · Crohn Disease (1) · Diabetic Retinopathy (1) · Heart Failure (1) · Macular Degeneration (1) · Renal Insufficiency, Chronic (1) · Retinal Diseases (1) · Retinal Vein Occlusion (1)
MediBeacon (8) · Aaron Cook (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Mustang Bio (1)
United States (10) · China (2)
Richard B Dorshow, PhD (7) · Aaron M Cook, PharmD (1) · Dong Sun (1) · Juan-Carlos Aycinena, MD (1) · Lihua E Budde, MD (1) · Yanxia Yu (1) · Yuanyuan Luo (1)